Literature DB >> 25150312

Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122.

Y Yan, F Zhang, Q Fan, X Li, K Zhou.   

Abstract

Breast cancer is a highly aggressive malignancy and always has a poor prognosis. The current therapeutic strategies including surgery, chemotherapy and radiotherapy benefit little for patients survival. Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in a wide range of cancer cells, such as breast cancer, it also has cytotoxicity to normal cells. To improve the selectivity of TRAIL expression to breast cancer cells, we inserted miRNA response elements (MREs) of let-7 and miR-122 into a TRAIL-expressing adenoviral vector (Ad-TRAIL-MRE-7-122) to restrict its expression within breast cancer cells. qPCR assay confirmed that the levels of let-7 and miR-122 were downregulated in breast cancer samples and cell lines, compared with normal tissues and cell lines. Luciferase assay indicated that MREs of let-7 and miR-122 was able to confer luciferase expression with the selectivity to breast cancer. Ad-TRAIL-MRE-7-122 highly expressed TRAIL in breast cancer cells, but not in normal cells. The breast cancer-specific apoptosis was detected after the infection of Ad-TRAIL-MRE-7-122. The viability of breast cancer cells, rather than normal cells, was reduced by the treatment of Ad-TRAIL-MRE-7-122. Animal experiments further confirmed that Ad-TRAIL-MRE-7-122 and Ad-TRAIL both greatly impeded the growth of breast cancer xenograft in mice. Taken together, we constructed a TRAIL-expressing recombinant adenovirus regulated by MREs of let-7 and miR-122 and showed evidences that this strategy may be promising for breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25150312     DOI: 10.4149/neo_2014_082

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

1.  Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression.

Authors:  Wei Zhang; Qingru Zeng; Zhenying Ban; Jing Cao; Tianjiao Chu; Dongmei Lei; Chi Liu; Wentao Guo; Xianxu Zeng
Journal:  Oncol Lett       Date:  2018-08-20       Impact factor: 2.967

Review 2.  Stabilization of miRNAs in esophageal cancer contributes to radioresistance and limits efficacy of therapy.

Authors:  Akshay Malhotra; Uttam Sharma; Shyamly Puhan; Naga Chandra Bandari; Anjali Kharb; P P Arifa; Lovlesh Thakur; Hridayesh Prakash; Karen M Vasquez; Aklank Jain
Journal:  Biochimie       Date:  2018-10-13       Impact factor: 4.079

Review 3.  Effects of noncoding RNAs in radiotherapy response in breast cancer: a systematic review.

Authors:  Tayebeh Oghabi Bakhshaiesh; Rezvan Esmaeili
Journal:  Cell Cycle       Date:  2022-02-02       Impact factor: 5.173

Review 4.  MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.

Authors:  Gloria Bertoli; Claudia Cava; Isabella Castiglioni
Journal:  Theranostics       Date:  2015-07-13       Impact factor: 11.556

Review 5.  TRAIL, Wnt, Sonic Hedgehog, TGFβ, and miRNA Signalings Are Potential Targets for Oral Cancer Therapy.

Authors:  Ammad Ahmad Farooqi; Chih-Wen Shu; Hurng-Wern Huang; Hui-Ru Wang; Yung-Ting Chang; Sundas Fayyaz; Shyng-Shiou F Yuan; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Int J Mol Sci       Date:  2017-07-14       Impact factor: 5.923

6.  Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.

Authors:  Srinivasulu Yerukala Sathipati; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

7.  MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes.

Authors:  Z W Zhang; H Li; S S Chen; Y Li; Z Y Cui; J Ma
Journal:  Braz J Med Biol Res       Date:  2017-02-06       Impact factor: 2.590

Review 8.  Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy.

Authors:  Olivia A Diaz Arguello; Hidde J Haisma
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.